Discover undervalued stocks with Eulerpool.

Subscribe for $2

PDS Biotechnology Stock PDSB

Price

0
Today +/-
-0
Today %
-0 %

PDS Biotechnology stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the PDS Biotechnology stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the PDS Biotechnology stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the PDS Biotechnology stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze PDS Biotechnology's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

PDS Biotechnology Stock Price History

DatePDS Biotechnology Price
10/11/20250 undefined
10/10/20250.95 undefined
10/10/20250.96 undefined
10/9/20251.01 undefined
10/8/20251.02 undefined
10/7/20250.99 undefined
10/6/20250.98 undefined
10/3/20251.04 undefined
10/3/20251.04 undefined
10/2/20251.03 undefined
10/1/20251.05 undefined
9/29/20251.01 undefined
9/28/20251.01 undefined
9/25/20251.02 undefined
9/24/20251.03 undefined
9/24/20251.08 undefined
9/24/20251.08 undefined
9/23/20251.05 undefined
9/22/20251.09 undefined
9/19/20251.06 undefined
9/19/20251.07 undefined
9/18/20251.15 undefined
9/17/20251.18 undefined
9/16/20251.21 undefined
9/15/20251.16 undefined
9/12/20251.21 undefined
9/12/20251.20 undefined

PDS Biotechnology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into PDS Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PDS Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PDS Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PDS Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PDS Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PDS Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PDS Biotechnology’s growth potential.

PDS Biotechnology Revenue, EBIT and net profit per share

DatePDS Biotechnology RevenuePDS Biotechnology EBITPDS Biotechnology Net Income
2030e230.55 M undefined0 undefined75.15 M undefined
2029e108.89 M undefined44.68 M undefined21.4 M undefined
2028e1.94 M undefined-61.67 M undefined-33.53 M undefined
2027e0 undefined-52.67 M undefined-36.94 M undefined
2026e0 undefined-44.87 M undefined-34.56 M undefined
2025e0 undefined-38.28 M undefined-39.16 M undefined
20240 undefined-36.32 M undefined-37.61 M undefined
20230 undefined-43.05 M undefined-42.94 M undefined
20220 undefined-41.67 M undefined-40.85 M undefined
20210 undefined-21.44 M undefined-16.92 M undefined
20200 undefined-14.9 M undefined-14.85 M undefined
20190 undefined-15.01 M undefined-7 M undefined
20180 undefined-31.09 M undefined-40.87 M undefined
20170 undefined-51.97 M undefined-50.86 M undefined
20160 undefined-39.51 M undefined-38.82 M undefined
20150 undefined-26.5 M undefined-32.44 M undefined
20140 undefined-13.19 M undefined-13.78 M undefined
20130 undefined-6.49 M undefined-7.96 M undefined
20120 undefined-4.69 M undefined-4.71 M undefined

PDS Biotechnology Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
00000000000000001108230
-----------------10,700.00112.96
-------------------
0000000000000000000
-4-7-13-32-38-50-40-7-14-16-40-42-37-39-34-36-332175
-75.0085.71146.1518.7531.58-20.00-82.50100.0014.29150.005.00-11.905.41-12.825.88-8.33-163.64257.14
1.351.351.350.41.441.521.564.8716.7525.628.630.9536.45000000
- - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The PDS Biotechnology Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the PDS Biotechnology is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (k)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (k)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2012201320142015201620172018201920202021202220232024
                         
0.17.913.7130.2106.488.134.612.228.865.273.856.5641.69
0000000000000
0000000000000
0000000000000
00.21.71.11112.31.51.62.72.493.36
0.18.115.4131.3107.489.135.614.530.366.876.559.0645.05
00.11.42.83.43.40.400.60.40.50.340.3
0000000000000
0000000000000
0000000000000
0000000000000
0100200100100100100000000
00.21.62.93.53.50.500.60.40.50.340.3
0.18.317134.2110.992.636.114.530.967.27759.3945.36
                         
4.320.736.8000000000.010.01
0.40.72184.7190.3214.3222.640.670.9123.9145.6170.62201.1
-8.1-16-29.8-62.3-101.1-151.9-192.8-28.9-43.8-60.7-101.6-144.5-182.11
0000000000000
0000000000000
-3.45.49122.489.262.429.811.727.163.24426.1319
2.71.122.63.54.40.41.21.41.31.26.981.68
0.60.71.53.73.25.40.41.11.92.48.52.422.84
0000005.60.500000
200000000000000
000.32.303.100000.14.2212.56
3.51.83.88.66.712.96.42.83.33.79.813.6317.09
002.531517.4000023.219.639.27
0000000000000
01.61.7000000.50.2000
01.64.231517.4000.50.223.219.639.27
3.53.4811.621.730.36.42.83.83.93333.2626.35
0.18.817134110.992.736.214.530.967.17759.3945.36
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of PDS Biotechnology provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand PDS Biotechnology's financial health and stability.

Assets

PDS Biotechnology's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that PDS Biotechnology must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of PDS Biotechnology after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into PDS Biotechnology's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-4-6-12-28-38-50-40-7-14-16-40-42
000000000000
000000000000
2-21103-3-41040
0127111318-318159
000001100003
000000000000
-2-8-9-21-32-40-33-18-13-12-25-33
000-100000000
000-1000290000
0000000290000
000000000000
003295-20000250
215141380170029481016
21516139922-20029483416
---1.00-1.00--------
000000000000
075116-23-18-531216368-17
-2.25-8.18-10.6-23.06-32.88-40.89-33.15-18.07-13.15-12.49-25.71-33.64
000000000000

PDS Biotechnology stock margins

The PDS Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PDS Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PDS Biotechnology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PDS Biotechnology's sales revenue. A higher gross margin percentage indicates that the PDS Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PDS Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PDS Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PDS Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PDS Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PDS Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PDS Biotechnology Margin History

PDS Biotechnology Gross marginPDS Biotechnology Profit marginPDS Biotechnology EBIT marginPDS Biotechnology Profit margin
2030e0 %0 %32.6 %
2029e0 %41.03 %19.66 %
2028e0 %-3,182.02 %-1,730.22 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

PDS Biotechnology Stock Sales Revenue, EBIT, Earnings per Share

The PDS Biotechnology earnings per share therefore indicates how much revenue PDS Biotechnology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue PDS Biotechnology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PDS Biotechnology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PDS Biotechnology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PDS Biotechnology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PDS Biotechnology Revenue, EBIT and net profit per share

DatePDS Biotechnology Sales per SharePDS Biotechnology EBIT per sharePDS Biotechnology Earnings per Share
2030e4.94 undefined0 undefined1.61 undefined
2029e2.34 undefined1.23 undefined0.46 undefined
2028e0.04 undefined-1.69 undefined-0.72 undefined
2027e0 undefined-1.44 undefined-0.79 undefined
2026e0 undefined-1.23 undefined-0.74 undefined
2025e0 undefined-1.05 undefined-0.84 undefined
20240 undefined-1 undefined-1.03 undefined
20230 undefined-1.39 undefined-1.39 undefined
20220 undefined-1.46 undefined-1.43 undefined
20210 undefined-0.84 undefined-0.66 undefined
20200 undefined-0.89 undefined-0.89 undefined
20190 undefined-3.08 undefined-1.44 undefined
20180 undefined-19.93 undefined-26.2 undefined
20170 undefined-34.19 undefined-33.46 undefined
20160 undefined-27.44 undefined-26.96 undefined
20150 undefined-66.25 undefined-81.1 undefined
20140 undefined-9.77 undefined-10.21 undefined
20130 undefined-4.81 undefined-5.9 undefined
20120 undefined-3.47 undefined-3.49 undefined

PDS Biotechnology business model

PDS Biotechnology Corporation is a biopharmaceutical company founded in 2005. It is based in New Jersey, USA and employs around 35 employees. The company specializes in the development of drugs and therapies for the treatment of cancer and infectious diseases. PDS Biotechnology's business model is based on the use of a technology platform called Versamune®. This platform allows for the embedding of immunomodulatory agents in vaccines and cancer therapies. The goal is to activate and strengthen the body's immune defense against cancer and infections. PDS has four different divisions: cancer immunotherapies, infectious diseases, vetmedica, and research services. PDS's cancer immunotherapies focus on stimulating the immune system to help the body recognize and fight cancer cells. The Versamune® technology is used in combination with peptide-based vaccines. Versamune® is intended to help generate a strong and sustained immune response. The most advanced projects in cancer immunotherapy include PD1 vaccines and the PD1 vaccine combination program. PDS is also working on the development of Versamune®-based treatment options in the areas of infectious diseases and vetmedica. Advanced platform technologies have been developed based on the use of Versamune® and choice peptide fusion proteins. In the field of research services, PDS offers a range of services related to its technology platform. These include the manufacturing of Versamune® products, preclinical studies, as well as analysis and consulting. One of PDS's projects, currently being tested in clinical phase IIa, is a vaccine against human papillomavirus (HPV). HPV is a virus that plays a significant role in the development of various types of cancer, such as cervical cancer. The vaccine aims to strengthen the immune system against HPV and thereby reduce the risk of developing cancer. In addition to developing new drugs, PDS has also focused on improving existing treatment options. The company collaborates closely with research institutions and other companies to leverage new insights and technologies in order to develop better therapies. PDS Biotechnology is an emerging company with promising products and a strong commitment to developing groundbreaking therapies for the treatment of cancer and infectious diseases. Through the use of its Versamune® technology and expertise in immunotherapy, the company has the potential to change the future of medicine and improve the lives of millions of people. PDS Biotechnology is one of the most popular companies on Eulerpool.com.

PDS Biotechnology SWOT Analysis

Strengths

PDS Biotechnology Corp possesses several strengths that contribute to its success:

  • Strong Intellectual Property: PDS Biotechnology has a robust portfolio of patents and intellectual property rights, providing a competitive advantage in the biotechnology industry.
  • Cutting-Edge Technology: The company's innovative platform technology, known as Versamune®, has the potential to revolutionize cancer immunotherapy and infectious disease treatment.
  • Experienced Management Team: PDS Biotechnology is led by a diverse team of industry experts with extensive experience in biotechnology, drug development, and commercialization.
  • Strategic Partnerships: The company has established collaborations with renowned research institutions and pharmaceutical companies, enhancing its research capabilities and market reach.

Weaknesses

While PDS Biotechnology Corp has numerous strengths, it also faces some weaknesses:

  • Financial Constraints: As a biotechnology startup, PDS Biotechnology may face challenges in securing sufficient funding for its research and development activities and scaling up its operations.
  • Dependency on Clinical Trials: The company's success heavily relies on the outcomes of ongoing clinical trials, making it susceptible to uncertainties and potential setbacks.
  • Limited Product Portfolio: As of now, PDS Biotechnology's product pipeline is primarily focused on a few therapeutic areas, leaving it potentially vulnerable to market fluctuations or shifts in medical trends.

Opportunities

PDS Biotechnology Corp can leverage the following opportunities for further growth:

  • Rising Demand for Immunotherapy: The increasing global prevalence of cancer and infectious diseases, coupled with the growing recognition of immunotherapy, presents a significant market opportunity for PDS Biotechnology to capitalize on.
  • Market Expansion: The company can explore partnerships or licensing agreements to expand its product portfolio and enter new therapeutic areas or geographical markets.
  • Government Support and Funding: PDS Biotechnology can take advantage of government initiatives and grants targeting the biotechnology sector, providing additional financial support and resources.

Threats

PDS Biotechnology Corp should be mindful of the following threats that could impact its growth and success:

  • Intense Competition: The biotechnology industry is highly competitive, with numerous established players and new entrants. PDS Biotechnology must continually innovate and differentiate itself to maintain a competitive edge.
  • Regulatory and Compliance Challenges: Stringent regulations and approval processes imposed by regulatory authorities can pose obstacles and delays in bringing new products to market.
  • Technological Obsolescence: Rapid advancements in biotechnology and immunotherapy may render PDS Biotechnology's technology or products outdated or less effective unless the company keeps pace with industry advancements.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

PDS Biotechnology Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

PDS Biotechnology historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

PDS Biotechnology shares outstanding

The number of shares was PDS Biotechnology in 2024 — This indicates how many shares 36.453 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue PDS Biotechnology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates PDS Biotechnology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of PDS Biotechnology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating PDS Biotechnology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

PDS Biotechnology stock splits

In PDS Biotechnology's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for PDS Biotechnology.

PDS Biotechnology latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.24 -0.21  (11.76 %)2025 Q2
3/31/2025-0.25 -0.21  (16.53 %)2025 Q1
12/31/2024-0.28 -0.21  (25.58 %)2024 Q4
9/30/2024-0.28 -0.29  (-2.15 %)2024 Q3
6/30/2024-0.34 -0.23  (33.29 %)2024 Q2
3/31/2024-0.37 -0.3  (19.79 %)2024 Q1
12/31/2023-0.45 -0.35  (21.75 %)2023 Q4
9/30/2023-0.45 -0.35  (23.01 %)2023 Q3
6/30/2023-0.35 -0.37  (-4.49 %)2023 Q2
3/31/2023-0.31 -0.32  (-2.63 %)2023 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the PDS Biotechnology stock

Eulerpool World ESG Rating (EESG©)

41/ 100

🌱 Environment

43

👫 Social

50

🏛️ Governance

29

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

PDS Biotechnology shareholders

%
Name
Stocks
Change
Date
4.79520 % Armistice Capital LLC2,236,000-2,183,0006/30/2025
4.18474 % The Vanguard Group, Inc.1,951,343441,1226/30/2025
1.48159 % Bedu-Addo (Frank)690,86604/17/2025
1.08318 % BlackRock Institutional Trust Company, N.A.505,08724,1186/30/2025
0.95455 % Sykes (Richard)445,10804/17/2025
0.90976 % UBS Financial Services, Inc.424,221178,8956/30/2025
0.89628 % Geode Capital Management, L.L.C.417,934-19,9476/30/2025
0.53614 % William Blair & Company, L.L.C. (Research)250,000-7,2006/30/2025
0.53404 % Citadel Advisors LLC249,025249,0256/30/2025
0.28594 % State Street Global Advisors (US)133,33306/30/2025
1
2
3
4
5
...
10

PDS Biotechnology Executives and Management Board

Dr. Frank Bedu-Addo

(60)
PDS Biotechnology President, Chief Executive Officer, Director (since 2019)
Compensation 2.26 M

Dr. Gregory Conn

(70)
PDS Biotechnology Chief Scientific Officer
Compensation 1.68 M

Dr. Kirk Shepard

(74)
PDS Biotechnology Chief Medical Officer
Compensation 1.33 M

Mr. Stephan Toutain

(59)
PDS Biotechnology Chief Operating Officer
Compensation 939,788

Mr. Stephen Glover

(65)
PDS Biotechnology Independent Chairman of the Board
Compensation 114,074
1
2
3

PDS Biotechnology Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
NetScientific Stock
NetScientific
SupplierCustomer0,710,280,64
Merck & Co Stock
Merck & Co
SupplierCustomer0,65-0,14-0,47-0,67-0,46
Merck Stock
Merck
SupplierCustomer-0,170,440,700,890,250,72
1

Most common questions regarding PDS Biotechnology

What values and corporate philosophy does PDS Biotechnology represent?

PDS Biotechnology Corp represents a commitment to advancing healthcare through innovative biotechnological solutions. The company's corporate philosophy revolves around developing novel immunotherapies to effectively treat various types of cancer and infectious diseases. PDS Biotechnology Corp focuses on leveraging its proprietary Versamune® platform to create targeted therapies that enhance the immune system's ability to combat disease. This approach aligns with their ultimate goal of improving patient outcomes and quality of life. With a strong emphasis on research, clinical development, and collaboration with key industry stakeholders, PDS Biotechnology Corp strives to make a significant impact on the future of immunotherapy.

In which countries and regions is PDS Biotechnology primarily present?

PDS Biotechnology Corp is primarily present in the United States.

What significant milestones has the company PDS Biotechnology achieved?

PDS Biotechnology Corp has achieved significant milestones in its journey. The company has successfully developed Versamune®, a proprietary clinical-stage immunotherapy platform, which has shown promising results in preclinical and early clinical studies. PDS Biotechnology Corp has also made progress in its partnership with the National Cancer Institute (NCI) to advance cancer vaccines using its Versamune® platform. Additionally, the company has garnered attention for its involvement in the fight against HPV-associated cancers, including the initiation of a Phase 2 clinical trial for its lead candidate, PDS0101. Overall, PDS Biotechnology Corp continues to make important strides in developing innovative immunotherapies to address major medical challenges.

What is the history and background of the company PDS Biotechnology?

PDS Biotechnology Corp is a leading biotechnology company specializing in developing and commercializing novel immunotherapies for cancer and infectious diseases. Founded in 2005, the company has focused on its proprietary Versamune® platform technology, which activates the immune system for an effective response against various diseases. PDS Biotechnology Corp has conducted extensive research and clinical trials to demonstrate the potential of its platform in treating HPV-associated cancers, including cervical, head, and neck cancers. With its innovative approach and promising pipeline, PDS Biotechnology Corp is committed to advancing immunotherapies that have the potential to revolutionize the treatment landscape for patients worldwide.

Who are the main competitors of PDS Biotechnology in the market?

Some of the main competitors of PDS Biotechnology Corp in the market include companies like Merck & Co., Inc., Bristol-Myers Squibb Company, and AstraZeneca PLC.

In which industries is PDS Biotechnology primarily active?

PDS Biotechnology Corp is primarily active in the biotechnology industry.

What is the business model of PDS Biotechnology?

The business model of PDS Biotechnology Corp focuses on developing and commercializing novel immunotherapies for the treatment of various types of cancer. By leveraging its proprietary Versamune® platform, PDS Biotechnology aims to stimulate the immune system, enhancing its ability to recognize and destroy tumors. This innovative approach combines immunotherapy with precision medicine to deliver more effective and individualized cancer treatments. PDS Biotechnology's dedication to advancing immunotherapies positions them as a key player in the biotechnology industry, contributing to the development of potentially life-saving treatments for cancer patients.

What is the P/E ratio of PDS Biotechnology 2025?

The P/E ratio cannot be calculated for PDS Biotechnology at the moment.

What is the P/S ratio of PDS Biotechnology 2025?

The P/S cannot be calculated for PDS Biotechnology currently.

What is the Quality Investing of PDS Biotechnology?

The Quality Investing for PDS Biotechnology is 4/10.

What is the revenue of PDS Biotechnology 2025?

The revenue cannot currently be calculated for PDS Biotechnology.

How high is the profit of PDS Biotechnology 2025?

The expected PDS Biotechnology profit is -39.16 M USD.

What is the business model of PDS Biotechnology

PDS Biotechnology Corp is a biopharmaceutical company specializing in the research and development of immunotherapeutic cancer treatments. The company utilizes a proprietary platform technology called Versamune® for the development of immunotherapeutics for treating various types of cancer. The business model of PDS Biotechnology Corp consists of two main divisions: research and product development, and strategic partnerships. The company's research and product development division focuses on developing immunotherapeutics based on Versamune®. This platform technology consists of a proprietary combination of molecules that activate the immune system and program it to specifically recognize and destroy cancer cells. The main product of PDS Biotechnology Corp currently is an immunotherapeutic called PDS0101, which was developed based on Versamune® and the PD-1 antigen. PDS0101 is currently in Phase 2 clinical development and is being tested for the treatment of HPV-associated cancer. The company also has other immunotherapeutics in the pipeline that have been developed based on Versamune® and could be used for the treatment of breast cancer, lung cancer, and other types of cancer. PDS Biotechnology Corp's strategic partnerships focus on collaborating with other companies and institutions to enhance access to resources and expertise. For example, the company is currently working with the National Cancer Institute to test its immunotherapeutics in clinical trials. In another collaboration, PDS Biotechnology Corp has entered into a partnership agreement with Farmacore Biotechnologia to develop and market its immunotherapeutics in Brazil and other Latin American countries. The business model of PDS Biotechnology Corp has the advantage of operating in a rapidly growing market. Immunotherapy has gained significant importance in recent years and offers a promising new approach to cancer treatment. This market is expected to continue growing in the coming years as more companies and research institutions invest in the development of immunotherapeutics. The company is also operating in a market segment that is traditionally dominated by large pharmaceutical companies. Most of the major pharmaceutical companies are currently investing substantial resources in immunotherapy development, creating intense competition. However, smaller companies like PDS Biotechnology Corp have the opportunity to focus on more specific indications and respond quickly to changes in market demand, as many of the large pharmaceutical companies are limited in the number of product candidates they can focus on. In summary, the business model of PDS Biotechnology Corp aims to develop innovative immunotherapeutics for cancer treatment while also building partnerships to improve access to resources and expertise. With its proprietary Versamune® platform technology and increasing presence in Latin America, the company has good growth prospects in a rapidly evolving market.

What is the PDS Biotechnology dividend?

PDS Biotechnology pays a dividend of 0 USD distributed over payouts per year.

How often does PDS Biotechnology pay dividends?

The dividend cannot currently be calculated for PDS Biotechnology or the company does not pay out a dividend.

What is the PDS Biotechnology ISIN?

The ISIN of PDS Biotechnology is US70465T1079.

What is the PDS Biotechnology WKN?

The WKN of PDS Biotechnology is A2PF3F.

What is the PDS Biotechnology ticker?

The ticker of PDS Biotechnology is PDSB.

How much dividend does PDS Biotechnology pay?

Over the past 12 months, PDS Biotechnology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PDS Biotechnology is expected to pay a dividend of 0 USD.

What is the dividend yield of PDS Biotechnology?

The current dividend yield of PDS Biotechnology is .

When does PDS Biotechnology pay dividends?

PDS Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PDS Biotechnology?

PDS Biotechnology paid dividends every year for the past 0 years.

What is the dividend of PDS Biotechnology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PDS Biotechnology located?

PDS Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von PDS Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PDS Biotechnology from 10/12/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/12/2025.

When did PDS Biotechnology pay the last dividend?

The last dividend was paid out on 10/12/2025.

What was the dividend of PDS Biotechnology in the year 2024?

In the year 2024, PDS Biotechnology distributed 0 USD as dividends.

In which currency does PDS Biotechnology pay out the dividend?

The dividends of PDS Biotechnology are distributed in USD.

All fundamentals about PDS Biotechnology

Our stock analysis for PDS Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PDS Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.